1. India Stocks

  2. •

    Health technology

  3. •

    Pharmaceuticals: major
Vasundhara Rasayans Ltd.

Vasundhara Rasayans Ltd.

BBSE:VRL
130.35
INR
-2.65
(-1.99%)
18.58EPS
9.10P/E
537.14MMarket Cap
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
2026 Y
TTM
Revenue per Share
65.63
58.31
48.26
48.6
52.22
62.2
66.97
71.36
84.17
119.38
115.67
106.95
112.41
110.47
Basic EPS, GAAP
4.43
1.84
0.74
1.45
20.51
4.57
9.4
9.24
6.84
17.59
18.31
13.36
18.22
18.58
Free Cash Flow per Basic Share
8.44
-1.56
3.45
7.38
-33.68
0.91
0.72
-0.66
23.76
-20.71
13.12
-19.68
-5.92
- -
Dividend per Share
0.58
0.58
0.6
- -
1.21
1.2
1.2
1.5
1.5
1
1.99
2
2
- -
Book Value per Share
20.49
21.72
22.46
22.71
43.22
46.59
54.78
62.52
67.76
84.38
100.49
111.88
128.61
- -
Tangible Book Value per Share
20.49
21.72
22.46
22.71
43.22
46.59
54.78
62.52
67.76
84.38
100.49
111.88
128.61
- -
Basic Weighted Avg Shares
3
3
3
3
3
3
3
3
3
3
3
3
3
3
Sales/Revenue/Turnover
209
185
153
154
166
198
213
227
268
379
370
340
357
351
Operating Margin (%)
13
6.24
5.04
7.26
9.14
6.51
13.32
13.48
7.82
14.3
16.66
11.04
15.37
16.22
Depreciation Expense
9
5
6
6
3
- -
- -
1
1
1
3
4
4
5
Net Income, GAAP
14
6
2
5
65
15
30
29
22
56
59
42
58
59
Effective Tax Rate (%)
34.07
33.69
44.57
59.64
28
29.97
23.5
25.9
28.68
25.21
25.78
26.37
26.38
25.88
Profit Margin (%)
6.75
3.15
1.54
2.99
39.28
7.35
14.04
12.94
8.12
14.74
15.83
12.49
16.21
16.82
Working Capital
21
9
7
11
135
148
173
108
204
258
303
335
387
- -
LT Debt
14
12
4
- -
- -
- -
- -
- -
- -
- -
8
5
3
- -
Total Equity
65
69
71
72
137
148
174
199
215
268
319
356
409
- -
Return on Invested Capital (%)
12.37
4.98
1.82
3.79
39.38
3.85
10.51
9.77
6.36
17.6
13.9
7.45
9.71
- -
Return on Capital (%)
15.81
7.77
2.48
5.41
52.04
9.7
18.44
16.02
10.32
21.38
18.5
12.07
14.76
- -
Return on Common Equity (%)
23.88
8.7
3.36
6.43
62.23
10.18
18.55
15.75
10.49
23.12
19.94
12.58
15.15
- -

Capital Structure

INR

•

in mil. unless spec.
Dec'26
Mar'26
Jun'27
ST Debt
- -
15
- -
LT Borrowings
- -
3
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
3
3
3
Market Capitalization
540
336
537

Working Capital

INR

•

in mil. unless spec.
Dec'26
Mar'26
Jun'27
Total Current Assets
- -
453
- -
Cash, Cash Equivalents & STI
- -
50
- -
Accounts Receivable, Net
- -
75
- -
Inventories
- -
15
- -
Total Current Liabilities
- -
66
- -
Payables & Accruals
- -
- -
- -
ST Debt
- -
15
- -
Deferred Revenue
- -
- -
- -

Growth Rates

INR

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
20.92%
15.65%
14.95%
Free Cash Flow
-515.33%
-879.34%
-69.91%
Net Income, GAAP
157.87%
28.99%
36.33%
Sales/Revenue/Turnover
9.58%
10.85%
5.1%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

INR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
76
98
88
78
340
2026
76
88
74
119
357
2027
69
- -
- -
- -
- -

Quarterly Earnings Per Share

INR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
2.71
4.61
4.57
1.43
13.36
2026
1.8
6.47
2.27
7.8
18.22
2027
2.04
- -
- -
- -
- -

Quarterly Dividends Per Share

INR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
- -
- -
- -
- -
2
2026
- -
- -
- -
- -
2
2027
- -
- -
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Rajesh Pokerna
Full Time Employees
41
Sector
Health technology
Industry
Pharmaceuticals: major
Address
Shed No. 42 Hyderabad TS India 500076
IPO Date
Sep 12, 2014
Website
vrlindia.in
Similar Companies
Eli Lilly and Company (NYSE:LLY)
Novo Nordisk A/S (NYSE:NVO)
Johnson & Johnson (NYSE:JNJ)
Pfizer, Inc. (NYSE:PFE)
Dr. Reddy's Laboratories Ltd. (NSE:DRREDDY)
Divi's Laboratories Limited (NSE:DIVISLAB)
Business
Vasundhara Rasayans Limited is an Indian pharmaceutical ingredient manufacturer specializing in the production and export of antacid therapeutic active pharmaceutical ingredients (APIs). Founded in 1987 and headquartered in Hyderabad, the company operates manufacturing facilities in Mahad, Maharashtra, where it produces a broad range of antacid APIs including aluminum hydroxide gel, magnesium hydroxide, magaldrate, magnesium trisilicate, magnesium silicate, aluminum phosphate, and poly aluminum chloride. These products are offered in various forms such as paste, powder, and micronized grade powder, serving pharmaceutical, food, and chemical industries. The company also manufactures organic intermediates and dyes intermediates while providing technical backup support services. Additionally, Vasundhara produces products for non-pharmaceutical uses such as water treatment, lake color manufacture, construction chemicals, and cooking oil treatment. The company maintains manufacturing processes compliant with Good Manufacturing Practice (GMP) standards, including specialized facilities for Friedel-Crafts reaction and organic intermediate production with advanced contamination control systems like three-stage scrubbers and titanium cooling coil quenchers. Vasundhara Rasayans Limited's production capabilities emphasize environmental friendliness and quality assurance. The company serves both domestic and international markets, exporting its products globally. Recent major developments include the appointment of Shri Ashok Kumar Jain as an Additional Independent Director and Shri Kodakandla Sidarsanam as a Whole-time Director to strengthen corporate governance. In 2025, Vasundhara declared a Rs. 2 per share dividend reflecting operational continuity despite financial challenges indicated by a recent decline in stock price and profits. The company remains focused on expanding its product offerings and technical support while maintaining sustainable manufacturing practices. Vasundhara Rasayans Limited operates as a subsidiary of P&J Cretechem Private Limited and continues to innovate in antacid APIs and related chemical products. This description reflects the company’s comprehensive product portfolio, manufacturing sophistication, geographical presence in India with global export reach, and recent corporate governance enhancements and dividend announcement as of late 2025.